Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)

INTRODUCTION: Belantamab mafodotin (BM) is a new anti-BCMA antibody–drug conjugate, recently approved for triple-class relapsed and refractory multiple myeloma (RRMM). We assessed real-world outcomes with BM in patients under the Spanish Expanded Access Program (EAP). METHODS: We conducted an observ...

Descripción completa

Detalles Bibliográficos
Autores principales: Alegre, Adrián, Benzo, Gonzalo, Alonso, Rafael, Martínez-López, Joaquín, Jimenez-Ubieto, Ana, Cuéllar, Clara, Askari, Elham, Prieto, Elena, Aláez, Concepción, Aguado, Beatriz, Velasco, Alberto, Krsnik, Isabel, Bocanegra, Ana, Llorente, Laura, Muñoz-Linares, Cristina, Morales, Ana, Giménez, Eugenio, Iglesias, Rebeca, Martínez-Chamorro, Carmen, Alonso, Aránzazu, Jiménez-Montes, Carmen, Blanchard, María J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744371/
https://www.ncbi.nlm.nih.gov/pubmed/36509945
http://dx.doi.org/10.1007/s40487-022-00212-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744371/
https://www.ncbi.nlm.nih.gov/pubmed/36509945
http://dx.doi.org/10.1007/s40487-022-00212-5

Ejemplares similares